Company intelligence / Profile preview
Windtree Therapeutics, Inc.
Warrington, Pennsylvania, United Stateswindtreetx.com ↗
- Ownership
- Public · WINT
- Employees
- ~15
- Development stage
- Phase 2
01
Overview
Lead candidate istaroxime has completed Phase 2 trials for acute heart failure and cardiogenic shock with positive results. The company is also developing preclinical SERCA2a activators and precision aPKCi inhibitors for oncology applications.
- Therapeutic areas
- OncologyPulmonologyCardiovascularInfectious Diseases
- Modalities
- Small molecule drugsSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Chang Gung UniversityNew Growth AdvisorsVarian Biopharmaceuticals Inc.
04
Financials
- Market cap
- $20.2K
- Total revenue
- $0
- Enterprise value
- $12.7M
Beyond the preview
Go deeper on Windtree Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Windtree Therapeutics, Inc..